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How little  
patients know
How much do our patients know about 
their disease, and what information do 
they have about the treatment options 
available to them? We all know that 
patients know less than is optimal, but in 
this issue Finkelstein et al. provide a quan-
titative analysis of patients with chronic 
kidney disease. When they questioned a 
large number of such patients, they found 
that a third had very little or no informa-
tion about their disease or their options 
for treatment. Many did not have any 
real information on dialysis or transplan-
tation. After about four visits in a year, 
there was some improvement in their 
level of understanding of the disease, but 
even then, half of the patients reported 
knowledge only about hemo dialysis, 
peritoneal dialysis, or transplantation. 
These are distressing findings, and they 
show that we need to work much harder 
in educating our patients about their con-
dition and their options for treatment. 
See page 1178.
Candesartan and 
oxidative stress
Ang i ote ns i n  re c e ptor  b l o cke rs 
(ARBs) have become a mainstay of 
antihypertensive and antiproteinuric 
therapy. The pharmaceutical industry 
has continued to provide new ARBs 
to capture a share in this immense 
market. A hidden advantage of such a 
plethora of ‘me-too’ drugs is that some 
of them may have additional ‘nonspe-
cific’ effects that might themselves open 
the way for new therapeutic applica-
tions. Pharmaceutical chemistry is full 
of such applications, and in this issue 
Chen et al. provide a new example of 
these serendipitous findings. They 
found that candesartan, but not other 
ARBs, reduces reactive oxygen toxic 
by-products induced by tumor necrosis 
factor in cultured proximal tubular epi-
thelial cells. They further found that 
high doses of candesartan, but no other 
ARB, reduced renal redox homeostasis 
in vivo. These kinds of studies open the 
way for development of new therapeu-
tic agents. See page 1128.
Proteinase 3 and 
complementary 
proteinase 3 in ANCA
Some patients with anti-neutrophil cyto-
plasmic autoantibodies (ANCAs) have 
antibodies not only against proteinase 3 
but also against a complementary pro-
tein produced by the antisense strand 
of its RNA. But are these antibodies 
pathogenic? To examine this point, 
Yang et al. attempted to isolate CD4 cells 
primed for the complementary pro-
tein. They cultured Th1 cells from such 
patients and found that about half of the 
patients had memory T cells reactive to 
a peptide present in the complementary 
protein. These cells were not detected 
in the other type of ANCA, in which 
myeloperoxidase was the ‘offending’ 
antigen. These studies raise the question 
of whether the autoimmune response 
is mediated by the complementary 
protein rather than the normal one. 
See page 1159.
